Buspirone in the treatment of levodopa induced dyskinesias.
作者信息
Kleedorfer B, Lees A J, Stern G M
出版信息
J Neurol Neurosurg Psychiatry. 1991 Apr;54(4):376-7. doi: 10.1136/jnnp.54.4.376-a.
Abstract
摘要
相似文献
1
Buspirone in the treatment of levodopa induced dyskinesias.丁螺环酮治疗左旋多巴诱发的运动障碍。
J Neurol Neurosurg Psychiatry. 1991 Apr;54(4):376-7. doi: 10.1136/jnnp.54.4.376-a.
2
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.持续皮下注射阿扑吗啡用于帕金森病左旋多巴诱导的剂末异动症的长期治疗
J Neurol Neurosurg Psychiatry. 1998 May;64(5):573-6. doi: 10.1136/jnnp.64.5.573.
3
Buspirone in levodopa-induced dyskinesias.丁螺环酮治疗左旋多巴诱发的运动障碍
Clin Neuropharmacol. 1994 Feb;17(1):73-82. doi: 10.1097/00002826-199402000-00008.
4
High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.高剂量培高利特单一疗法治疗严重左旋多巴诱发的运动障碍。
Mov Disord. 1996 May;11(3):327-9. doi: 10.1002/mds.870110319.
5
Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine.
Mov Disord. 1992;7(3):283-4. doi: 10.1002/mds.870070316.
6
[Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].[溴隐亭治疗帕金森病及左旋多巴诱发的异动症患者]
Ned Tijdschr Geneeskd. 1982 Apr 17;126(16):701-5.
7
Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.左旋多巴诱发的运动障碍与阿扑吗啡持续皮下输注：一项为期两年的前瞻性随访结果
Mov Disord. 2002 Jan;17(1):188-91. doi: 10.1002/mds.1276.
8
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.阿扑吗啡单一疗法治疗帕金森病难治性运动并发症：64例患者的长期随访研究
Mov Disord. 2002 Nov;17(6):1235-41. doi: 10.1002/mds.10281.
9
Apomorphine and diphasic dyskinesia.
Clin Neuropharmacol. 1994 Feb;17(1):99-102.
10
Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.晚期帕金森病的严重夜间异动症：临床描述、与血浆左旋多巴的关系及治疗
Mov Disord. 1994 Mar;9(2):173-7. doi: 10.1002/mds.870090208.
引用本文的文献
1
NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy.NLX-112随机2A期试验：安全性、耐受性、抗运动障碍及抗帕金森病疗效
Mov Disord. 2025 Jun;40(6):1134-1142. doi: 10.1002/mds.30175. Epub 2025 Mar 17.
2
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.新型获批及在研药物治疗帕金森病的运动症状。
Drugs. 2022 Jul;82(10):1027-1053. doi: 10.1007/s40265-022-01747-7. Epub 2022 Jul 16.
3
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.帕金森病伴发焦虑的丁螺环酮治疗试验：安全性和耐受性。
Parkinsonism Relat Disord. 2020 Dec;81:69-74. doi: 10.1016/j.parkreldis.2020.10.020. Epub 2020 Oct 13.
4
CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.临床试验要点 - 运动障碍
J Parkinsons Dis. 2019;9(3):449-465. doi: 10.3233/JPD-199002.
5
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.帕金森病的治疗策略：超越多巴胺能药物
Nat Rev Drug Discov. 2018 Nov;17(11):804-822. doi: 10.1038/nrd.2018.136. Epub 2018 Sep 28.
6
Non-dopamine receptor ligands for the treatment of Parkinson's disease. Insight into the related chemical/property space.用于治疗帕金森病的非多巴胺受体配体。对相关化学/性质空间的洞察。
Mol Divers. 2016 Feb;20(1):345-65. doi: 10.1007/s11030-015-9598-y. Epub 2015 May 9.
7
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.依托必利可对抗帕金森病中左旋多巴诱导的运动障碍：一项剂量探索研究。
Brain. 2015 Apr;138(Pt 4):963-73. doi: 10.1093/brain/awu409. Epub 2015 Feb 10.
8
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.5-羟色胺治疗大鼠帕金森病及左旋多巴诱导的异动症的副作用概况
Br J Pharmacol. 2015 Jan;172(1):119-30. doi: 10.1111/bph.12894. Epub 2014 Nov 24.
9
Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.5-羟色胺系统与基底节的相互作用：帕金森病中的功能意义和治疗前景。
Front Neural Circuits. 2014 Mar 17;8:21. doi: 10.3389/fncir.2014.00021. eCollection 2014.
10
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.导致帕金森病患者左旋多巴诱导运动障碍的血清素能机制。
J Clin Invest. 2014 Mar;124(3):1340-9. doi: 10.1172/JCI71640. Epub 2014 Feb 17.
本文引用的文献
1
Buspirone: chemical profile of a new class of anxioselective agents.丁螺环酮：一类新型抗焦虑药的化学特性
J Clin Psychiatry. 1982 Dec;43(12 Pt 2):4-10.
2
The modern management of Parkinson's disease.帕金森病的现代管理
J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):93-5. doi: 10.1136/jnnp.53.2.93.
3
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.胃复安和匹莫齐特在帕金森病及左旋多巴诱发的异动症中的应用
J Neurol Neurosurg Psychiatry. 1975 Apr;38(4):331-5. doi: 10.1136/jnnp.38.4.331.
Zotero 插件